{"organizations": [], "uuid": "b93fe93bfa19f9824005529070c2e5ee58d8de55", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-reports-q1/brief-aralez-pharmaceuticals-reports-q1-loss-per-share-of-0-29-idUSASC0A0DK", "country": "US", "domain_rank": 408, "title": "BRIEF-Aralez Pharmaceuticals Reports Q1 Loss Per Share Of $0.29", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T14:01:00.000+03:00", "replies_count": 0, "uuid": "b93fe93bfa19f9824005529070c2e5ee58d8de55"}, "author": "", "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-reports-q1/brief-aralez-pharmaceuticals-reports-q1-loss-per-share-of-0-29-idUSASC0A0DK", "ord_in_thread": 0, "title": "BRIEF-Aralez Pharmaceuticals Reports Q1 Loss Per Share Of $0.29", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "aralez pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8, 2018 / 11:05 AM / in 3 minutes BRIEF-Aralez Pharmaceuticals Reports Q1 Loss Per Share Of $0.29 Reuters Staff\nMay 8 (Reuters) - Aralez Pharmaceuticals Inc: * ARALEZ ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS\n* 1Q 2018 NET REVENUES INCREASED TO $38.1 MILLION VERSUS $26.0 MILLION IN 1Q 2017 * WITHDRAWING ITS PREVIOUS GUIDANCE\n* AS OF MARCH 31, 2018 HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.9 MILLION\n* ARALEZ - DETERMINED THERE IS REASONABLE POSSIBILITY CO WILL NOT HAVE SUFFICIENT LIQUIDITY TO FUND CURRENT & PLANNED OPERATIONS THROUGH NEXT 12 MONTHS\n* ARALEZ PHARMACEUTICALS - THERE IS SUBSTANTIAL DOUBT ABOUT COMPANYâ€™S ABILITY TO CONTINUE AS A GOING CONCERN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-08T14:01:00.000+03:00", "crawled": "2018-05-08T14:16:32.012+03:00", "highlightTitle": ""}